Institute of Microbiology, Chinese Academy of Sciences | China
Author Profile
Scopus
Early Academic Pursuits
Dr. Jianxun Qi laid a strong academic foundation in microbiology and virology, which paved the way for his remarkable contributions to structural biology and protein chemistry. His early focus was on understanding virus–host interactions, a field that would later define his scientific career and global recognition.
Professional Endeavors
Currently serving as a Professor at the Institute of Microbiology, Chinese Academy of Sciences (IMCAS), Dr. Qi has established himself as a leading scientist in viral pathogenesis and structural virology. In 2021, he was selected as a leading talent in science and technology innovation under China’s prestigious “Ten Thousand Talent Program.” His professional trajectory reflects dedication to advancing viral immunology and translational research with broad societal impact.
Contributions and Research Focus
Dr. Qi’s work centers on deciphering the structural mechanisms of virus–receptor interactions, shedding light on the molecular dynamics of pathogens such as Influenza virus, Coronaviruses, Ebola virus, Thogotovirus, ASFV, Coxsackievirus A10, and SFTSV. Through high-impact publications in Science, Nature, Cell, EMBO, PNAS, and Nature Communications, he has provided pivotal insights into viral entry, immune evasion, and vaccine design. Recent studies extend his expertise to epitope-based vaccine development and broad-spectrum antiviral engineering, offering innovative approaches to combat emerging infectious diseases.
Impact and Influence
With over 19,000 citations and an H-index of 64, Dr. Qi’s research has had a profound influence on the global scientific community. His findings have shaped understanding of pandemic threats, including MERS-CoV, SARS-CoV-2, and Ebola virus, directly informing vaccine strategies and therapeutic interventions. His recognition as a Highly Cited Researcher (2021–2024) and inclusion in Stanford University and Elsevier’s World’s Top 2% Scientists List underscore his international impact.
Academic Citations and Recognition
Dr. Qi’s groundbreaking studies—such as structural revelations on Influenza H7N9 (Science, 2013), MERS-CoV (Nature, 2013), and SARS-CoV-2 (Cell, 2020, 2022)—are extensively cited worldwide. His pioneering discoveries have garnered major honors, including the First Prize of the Beijing Science and Technology Award (2011) and the First Prize of the Chinese Preventive Medicine Association Science and Technology Award (2017).
Legacy and Future Contributions
Dr. Qi’s legacy lies in bridging fundamental virology with translational medicine, guiding the development of next-generation vaccines and antivirals. His continued exploration of viral mechanisms, coupled with collaborative innovations such as epitope vaccines and monoclonal antibody studies, positions him to contribute further to global preparedness against pandemics. Looking ahead, his research promises to expand the frontiers of viral immunology and structural vaccinology.
Conclusion
Dr. Jianxun Qi exemplifies scientific excellence through his persistent pursuit of knowledge, impactful research, and leadership in microbiology. His influential work on virus–host interactions and vaccine innovation has not only advanced academic discourse but also delivered tangible benefits to public health. As he continues to push boundaries in virology and immunology, his contributions will remain a cornerstone for future breakthroughs in infectious disease prevention and control.
Notable Publications
"T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots"
"Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2"
- Journal: Hlife
- Citation: 5
- Year: 2025
"Structural basis of DNA replication fidelity of the Mpox virus"
"Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2"
"Molecular mechanism of potently neutralizing human monoclonal antibodies against severe fever with thrombocytopenia virus infection"